Prof. Vincent Kelly is the Academic Director of the ARC Hub for Therapeutics, bringing a critical blend of world-class science and commercial vision to the Hub. A pioneering force in RNA-based nucleic acid technologies at Trinity College Dublin, he is responsible for accelerating the translation of fundamental research into real-world therapeutics. Prof. Kelly has a deep industry track record from his senior R&D experience at Banyu Pharmaceuticals (a subsidiary of Merck & Co.). He is a proven innovator and entrepreneur, holding 6 patent families and co-founding Azadyne Ltd., an RNA therapeutics company. His expertise, which includes the Transgenics facility, is vital for delivering impact alongside our biopharma partners.
Innovation Training for ARC Hub for Therapeutics Translational Researchers
To complement excellence in scientific research, successful commercialisation requires research teams to have a strong understanding of their target markets, the specific problems their technologies address, the competitive landscape, and the ability to...
